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(eGFR) of less than 60 ml/min, acute infection, 
drugs known to interfere with dabigatran (eg, 
amiodarone, verapamil).
In fasting citrated plasma samples following 
administration of dabigatran according to an in‑
dividual dosing scheme (1–24 h since the last 
dose), we measured aPTT, PT ‑INR (both Siemens, 
Marburg, Germany), serum creatinine with eGFR 
using the Chronic Kidney Disease Epidemiolo‑
gy Collaboration equation in a hospital labora‑
tory. Plasma concentrations of dabigatran were 
determined using the Hemoclot thrombin in‑
hibitor assay (HYPHEN BioMed, Neuville ‑sur‑
‑Oise, France) according to the manufacturer’s 
instructions. Briefly, a constant amount of hu‑
man thrombin was added to the diluted tested 
plasma mixed with a normal pooled human plas‑
ma and the measured TT was directly related to 
a concentration of dabigatran in the sample. In 
20 nonanticoagulated healthy individuals, we de‑
termined the same parameters to obtain the ref‑
erence values, ie, aPTT, 27.8 ±2.4 s (normal range, 
23.1–33.8 s); PT, 11.4 ±0.5 s (10.4–13.0 s); and 
INR, 1.0 ±0.05 (0.85–1.15 s). All control subjects 
had dabigatran concentrations below 35 ng/ml 
(the lower limit of measuring range).
Results In AF patients with normal creatinine 
levels (84.4 ±16.9 µmol/l; eGFR, 76 ±13.9 ml/min), 
plasma dabigatran concentrations ranged from 
35  to 321  ng/ml (median, 105  ng/ml; inter‑
quartile range, [IQR], 75–152 ng/ml). Patients 
who declared that the last dose of dabigatran 
was taken within 1 to 4 hours prior to blood col‑
lection (n = 23) had dabigatran concentrations 
from 38 to 321 ng/ml (median, 110 ng/ml; IQR, 
85–177 ng/ml), while those in whom blood was 
drawn after 4 hours from the last dose (n = 9) had 
dabigatran concentrations from 35 to 140 ng/ml 
(median, 58 ng/ml; IQR, 50–123 ng/ml) (P = 
0.036). There were 4 patients (12.5%) with dab‑
igatran concentrations of 50 ng/ml and lower, 
including 3 subjects who reported 12 hours or 
more from the drug intake and 1 who declared 
Introduction Dabigatran etexilate, a new oral di‑
rect thrombin inhibitor, has been shown to sur‑
pass therapy with warfarin, when given for pre‑
vention of stroke and systemic embolism in pa‑
tients with nonvalvular atrial fibrillation (AF).1,2 
Recently, it has been reported that higher dabi‑
gatran concentrations are associated with an el‑
evated bleeding rate and lower concentrations, 
with increased thromboembolic risk.3
Dabigatran prolongs activated partial throm‑
boplastin time (aPTT), thrombin time (TT), and 
ecarin clotting time with a slight increase in pro‑
thrombin time ‑international normalized ratio 
(PT ‑INR).2,4 Routine laboratory monitoring of 
dabigatran using clot ‑based assays is currently 
not recommended.4-6 However, there are situa‑
tions in which measurements of the anticoagu‑
lant effect of dabigatran are desirable, for exam‑
ple, in patients who experienced thromboembo‑
lism or bleeding events despite regular dabiga‑
tran intake.
We investigated the variation in plasma dabig‑
atran concentrations in AF patients with normal 
renal function in our outpatient clinic.
Patients and methods We studied 32 consecu‑
tive patients with permanent AF (13 women and 
19 men), aged 64.7 ±9.5 years, who were treated 
with dabigatran for 3 months or longer and com‑
plained of no bleeding or thromboembolic events 
over that period of time. Patients were recruit‑
ed at the Cardiology Clinic of the John Paul II 
Hospital, Kraków, Poland, from June to Novem‑
ber 2013. The risk for stroke and bleeding esti‑
mated with the CHA2DS2VASc and HAS ‑BLED 
scores was 2.9 ±1.3 (3–6 points, n = 18) and 
1.7 ±1.1 (3 points, n = 6), respectively. Twenty‑
‑eight patients (87.5%) were treated with dabig‑
atran at a dose of 150 mg twice daily and 4 with 
dabigatran at a dose of 110 mg owing to high 
bleeding risk. The exclusion criteria were acute 
thromboembolism within the preceding 1 month, 
cancer, chronic kidney disease stage 3 or high‑
er with an estimated glomerular filtration rate 
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outpatients with permanent AF and an eGFR ex‑
ceeding 60 ml/kg/min, not requiring reduction in 
dabigatran dosage for this reason, the levels were 
similar to the expected values5 with the peak/
trough ratio of about 2:1 as in the study by Reil‑
ly et al.,3 in which a validated high ‑performance 
liquid chromatography–tandem mass spectrom‑
etry was used to determine drug concentrations. 
We found a large variability in dabigatran concen‑
trations when determined in AF patients with 
the highest levels 1 to 4 hours after the last dose 
and an overlap of the results for samples taken 
at the peak anticoagulant activity versus the lat‑
er time. The blood sampling time is crucial for 
the interpretation of the test results6 as confirmed 
in our study. Patients’ age was identified to be 
the only independent predictor of dabigatran 
concentrations in our group. aPTT shows a lin‑
ear relationship with dabigatran concentrations 
up to the very high levels typical of overdose, af‑
ter which a flattering of the curve is observed.4,5 
Despite a significant, though moderate, correla‑
tion between aPTT and dabigatran concentrations 
estimated using the Hemoclot assay, aPTT does 
not allow quantitative assessment of dabigatran 
levels.2-5 Nevertheless, prolonged aPTT indicates 
the presence of the drug in the blood and, given 
the fact that all subjects (control and tested) with 
dabigatran levels of 35 ng/ml and less had nor‑
mal aPTT, it could be useful in patients sched‑
uled for major surgery with high bleeding risk 
in whom physicians are uncertain as to wheth‑
er anticoagulant effects of dabigatran subsid‑
ed.2,5 Although prolonged PT was observed with‑
in the first hours after the dabigatran intake, this 
parameter is much less sensitive to thrombin in‑
hibition than aPTT.5
Of note, we found that about 6% of patients 
with AF on dabigatran reported that the inter‑
vals between the 2 consecutive doses were longer 
than the recommended 12 hours. Good compli‑
ance is of key importance for good and safe anti‑
coagulation, especially in patients on new oral an‑
ticoagulants with a relatively short half ‑times.2,6
Our findings indicate that the measurement 
of plasma dabigatran concentrations is feasible 
in everyday practice and may support patient 
management if necessary, though the therapeu‑
tic range has not been determined yet.
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taking dabigatran 3 hours before the visit. Two 
patients with AF (6.3%) declared that more than 
12 hours elapsed since the last dose of dabigatran 
despite the fact that this anticoagulant should 
be taken every 12 hours. Dabigatran concentra‑
tions were weakly correlated with age (R2 = 0.21; 
P = 0.008) but not with eGFR, sex, and the time 
since the last dose (FIguRE). By analysis of covari‑
ance, after adjustment for sex (P = 0.4), the time 
of blood collection (P = 0.14), and creatinine lev‑
els (P = 0.54), age alone was an independent pre‑
dictor of the dabigatran concentration (F = 5.07, 
P = 0.033).
The median dabigatran concentration tend‑
ed to be higher in patients with a CHA2DS2VASc 
of 3 and higher as compared with those with 
a CHA2DS2VASc of 2 and lower (128 ng/ml vs. 
85 ng/ml, P = 0.06, respectively). There were no 
differences in patients with a HAS ‑BLED score 
of 0 to 1 and ≥2.
Routine coagulation tests showed pro‑
longed aPTT (43.1 ±8.8 s), PT (13.9 ±1.7 s), and 
INR (1.24 ±0.16) compared with controls (all 
P <0.0001). All patients on dabigatran except 
the 2 subjects with the drug concentration of 
35 ng/ml had prolonged aPTT. Positive linear 
correlations between dabigatran concentrations 
and aPTT (R2 = 0.48; P <0.0001) as well as PT (R2 = 
0.39, P = 0.0001) were observed (FIguRE).
To our knowledge, this study is the first to 
show the results of dabigatran monitoring using 
the Hemoclot assay recommended for this pur‑
pose in the European Union since 2013 in every‑
day practice in a Polish hospital. In typical stable 
FIguRE Associations of age and time since the last dose with plasma dabigatran 
concentrations and their correlations with coagulation times 
Abbreviations: aPTT – activated partial thromboplastin time, PT – prothrombin time
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